{"id":9692,"date":"2021-05-10T15:33:58","date_gmt":"2021-05-10T22:33:58","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9692"},"modified":"2021-05-12T15:34:36","modified_gmt":"2021-05-12T22:34:36","slug":"meta-analysis-of-risk-of-vaccine-induced-immune-thrombotic-thrombocytopenia-following-chadox1-s-recombinant-vaccine","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/10\/meta-analysis-of-risk-of-vaccine-induced-immune-thrombotic-thrombocytopenia-following-chadox1-s-recombinant-vaccine\/","title":{"rendered":"Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Pooled estimates of v<\/span><span style=\"font-weight: 400\">accine-induced immune thrombotic thrombocytopenia (VITT) <\/span><span style=\"font-weight: 400\">cumulative incidence among individuals who received <\/span><span style=\"font-weight: 400\">Oxford-AstraZeneca\/Covishield vaccine <\/span><span style=\"font-weight: 400\">in<\/span><span style=\"font-weight: 400\"> 10 countries found an overall risk of 1 in 139,000. For those aged 65 and over, the risk was about 1 in 1,000,000, while for those under 55, the risk was between 1 in 20,000 to 60,000. Risk also varied between countries in the analysis, with a<\/span><span style=\"font-weight: 400\"> cumulative<\/span><span style=\"font-weight: 400\"> incidence of 1.67 per 100,000 in the UK, and 5.06 per 100,000 in Norway. The authors note that <\/span><span style=\"font-weight: 400\">even the highest reported incidence in Norway is <\/span><span style=\"font-weight: 400\">lower than the risk of serious COVID-19 outcomes in areas with high community spread, as well as risk of serious injury requiring hospitalization or death as a result of driving.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Chan et al.\u00a0(May 8, 2021). Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine. Pre-print downloaded May 10 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.04.21256613\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.04.21256613<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Pooled estimates of vaccine-induced immune thrombotic thrombocytopenia (VITT) cumulative incidence among individuals who received Oxford-AstraZeneca\/Covishield vaccine in 10 countries found an overall risk of 1 in 139,000. For those aged 65 and over, the risk was about 1 in 1,000,000, while for those under 55, the risk was between 1 in 20,000&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/10\/meta-analysis-of-risk-of-vaccine-induced-immune-thrombotic-thrombocytopenia-following-chadox1-s-recombinant-vaccine\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[142],"topic":[31],"class_list":["post-9692","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccine","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9692"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9692\/revisions"}],"predecessor-version":[{"id":9693,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9692\/revisions\/9693"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9692"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}